shutterstock_1173953113_360b

360b / Shutterstock.com

2 May 2019Big Pharma

AstraZeneca partners on AI drug discovery collaboration

AstraZeneca has begun collaborating with UK-headquartered artificial intelligence (AI) company BenevolentAI to use AI and machine learning for the discovery and development of new treatments.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

AstraZeneca announces new R&D, AI centres in China

11 November 2019 AstraZeneca is planning to build a new global research and development centre in China.

Novartis and BenevolentAI sign AI oncology deal

9 September 2019 Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.

Novartis enters AI partnership with Oxford University

21 January 2019 Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

More on this story

AstraZeneca announces new R&D, AI centres in China

11 November 2019 AstraZeneca is planning to build a new global research and development centre in China.

Novartis and BenevolentAI sign AI oncology deal

9 September 2019 Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.

Novartis enters AI partnership with Oxford University

21 January 2019 Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

More on this story

AstraZeneca announces new R&D, AI centres in China

11 November 2019 AstraZeneca is planning to build a new global research and development centre in China.

Novartis and BenevolentAI sign AI oncology deal

9 September 2019 Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.

Novartis enters AI partnership with Oxford University

21 January 2019 Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB